United Therapeutics (UTHR) Net Income towards Common Stockholders Growth (3y) (2012 - 2026)
United Therapeutics (UTHR) Net Income towards Common Stockholders Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 51.28% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 2.94% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -70.54% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 4.50% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -7.75% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 66.11% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | -17.90% |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -38.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.50% |
| Dec 31, 2025 | 40.23% |
| Sep 30, 2025 | 12.28% |
| Jun 30, 2025 | 38.70% |
| Mar 31, 2025 | 10.33% |
| Dec 31, 2024 | 39.00% |
| Sep 30, 2024 | 23.85% |
| Jun 30, 2024 | 17.23% |
| Mar 31, 2024 | 121.27% |
| Dec 31, 2023 | 30.01% |
| Sep 30, 2023 | 16.05% |
| Jun 30, 2023 | 34.26% |
| Mar 31, 2023 | 20.49% |
| Dec 31, 2022 | 35.93% |
| Sep 30, 2022 | 21.81% |
| Jun 30, 2022 | -17.30% |
| Mar 31, 2022 | 35.45% |
| Dec 31, 2021 | 19.77% |
| Sep 30, 2021 | 15.17% |
| Jun 30, 2021 | -0.06% |